Morgan Stanley Intra Cellular Therapies, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Morgan Stanley holds 836,210 shares of ITCI stock, worth $106 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

836,210

Previous 1,029,869 18.8%

Holding current value

$106 Million

Previous $70.5 Million 13.32%

% of portfolio

0.0%

Previous 0.01%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$67.99 - $80.84 $13.2 Million - $15.7 Million	-193,659 Reduced 18.8%	836,210 $61.1 Million
Q2 2024 Oct 17, 2024	BUY	$64.76 - $79.84 $5.83 Million - $7.19 Million	90,072 Added 9.58%	1,029,869 $70.5 Million
Q2 2024 Aug 14, 2024	BUY	$64.76 - $79.84 $5.83 Million - $7.19 Million	90,072 Added 9.58%	1,029,869 $70.5 Million
Q1 2024 Oct 17, 2024	SELL	$64.37 - $75.65 $5.8 Million - $6.81 Million	-90,072 Reduced 8.75%	939,797 $65 Million
Q1 2024 Aug 16, 2024	SELL	$64.37 - $75.65 $19.5 Million - $22.9 Million	-302,223 Reduced 24.33%	939,797 $65 Million
Q1 2024 May 15, 2024	SELL	$64.37 - $75.65 $19.5 Million - $22.9 Million	-302,223 Reduced 24.33%	939,797 $65 Million
Q4 2023 Aug 16, 2024	BUY	$46.37 - $73.65 $9.84 Million - $15.6 Million	212,151 Added 20.6%	1,242,020 $89 Million
Q4 2023 Feb 13, 2024	BUY	$46.37 - $73.65 $14.2 Million - $22.6 Million	306,433 Added 32.75%	1,242,020 $89 Million
Q3 2023 Nov 15, 2023	SELL	$52.09 - $64.1 $4.78 Million - $5.89 Million	-91,838 Reduced 8.94%	935,587 $48.7 Million
Q2 2023 Aug 14, 2023	BUY	$54.67 - $66.44 $17.2 Million - $20.8 Million	313,800 Added 43.97%	1,027,425 $65.1 Million
Q1 2023 May 15, 2023	SELL	$43.8 - $56.99 $10.8 Million - $14.1 Million	-246,593 Reduced 25.68%	713,625 $38.6 Million
Q4 2022 Feb 14, 2023	BUY	$44.07 - $54.45 $3.96 Million - $4.89 Million	89,758 Added 10.31%	960,218 $50.8 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $3.97 Million - $5.57 Million	92,923 Added 11.95%	870,460 $40.5 Million
Q2 2022 Oct 27, 2022	BUY	$43.0 - $65.64 $5.31 Million - $8.11 Million	123,553 Added 18.89%	777,537 $44.4 Million
Q2 2022 Aug 15, 2022	BUY	$43.0 - $65.64 $5.31 Million - $8.11 Million	123,553 Added 18.89%	777,537 $44.4 Million
Q1 2022 Oct 27, 2022	SELL	$38.74 - $62.09 $4.79 Million - $7.67 Million	-123,553 Reduced 15.89%	653,984 $40 Million
Q1 2022 May 13, 2022	SELL	$38.74 - $62.09 $1.59 Million - $2.54 Million	-40,914 Reduced 5.89%	653,984 $40 Million
Q4 2021 Feb 14, 2022	SELL	$35.2 - $53.42 $1.52 Million - $2.3 Million	-43,122 Reduced 5.84%	694,898 $36.4 Million
Q3 2021 Nov 15, 2021	BUY	$28.72 - $42.49 $21.2 Million - $31.4 Million	738,020 New	738,020 $27.5 Million

Others Institutions Holding ITCI

# of Institutions

384

Shares Held

84.9M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $12B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account